Ingenium Pharmaceuticals AG
This article was originally published in Start Up
Executive Summary
Ingenium Pharmaceuticals AG is discovering drug targets through Deductive Genomics: observing gene function, or disease states, in mouse models and then reversing course to identify the responsible gene. By matching corresponding genes in the human genome, Ingenium hopes to accelerate drug discovery for immunology, neurobiology, metabolic diseases and cancer.